HomeEXEL • NASDAQ
add
Exelixis Inc
Previous close
$44.21
Day range
$44.09 - $44.91
Year range
$31.90 - $49.40
Market cap
11.84B USD
Avg Volume
3.07M
P/E ratio
18.60
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Revenue | 597.76M | 10.79% |
Operating expense | 322.82M | -3.45% |
Net income | 193.58M | 64.09% |
Net profit margin | 32.38 | 48.06% |
Earnings per share | 0.78 | 65.96% |
EBITDA | 263.78M | 35.07% |
Effective tax rate | 23.31% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 988.54M | -16.87% |
Total assets | 2.82B | -4.62% |
Total liabilities | 662.85M | -3.21% |
Total equity | 2.16B | — |
Shares outstanding | 268.11M | — |
Price to book | 5.49 | — |
Return on assets | 23.30% | — |
Return on capital | 28.17% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Net income | 193.58M | 64.09% |
Cash from operations | 290.32M | 7.00% |
Cash from investing | 25.40M | 111.70% |
Cash from financing | -103.86M | -1,923.38% |
Net change in cash | 211.87M | 253.78% |
Free cash flow | 205.41M | -32.03% |
About
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration for medullary thyroid cancer with clinical activity in several other types of metastatic cancer. Wikipedia
Founded
Nov 15, 1994
Headquarters
Website
Employees
1,147
